PARIS--(BUSINESS WIRE)-- Regulatory News:
BioAlliance Pharma’s (Paris:BIO) Board has approved the draft resolutions on Board changes, to be voted at the General Assembly Meeting on June 29, 2011.
Following Mr. André Ulmann and Mr. Gilles Marrache expressed wishes not to pursue their board mandate due to personal constraints, the Board thanks them for their commitment and contribution to its work and will propose their replacement at next General Assembly Meeting respectively by the company Financière de la Montagne, the first BioAlliance’s shareholder, represented by Mr. Nicolas Trebouta, and by Mr. David Solomon.
Moreover, the Board will propose the ratification of Mr. Patrick Langlois cooptation as new board member as well as the nomination of Mrs. Judith Greciet, presently Chief Operating Officer of BioAlliance Pharma.
The Board of Directors will then comprise 9 members, including 4 new administrators.
Besides, the Board intends to appoint Patrick Langlois as its new President after André Ulmann’s resignation following the General Assembly.
« Considering BioAlliance’s challenges, I have proposed the cooptation of Patrick Langlois for its expertise in corporate development, and the nomination of two other members, first to reinforce shareholders’ representation at the Board and secondly to enrich the group with international visions, specially Anglo-Saxon culture”, commented André Ulmann.
Patrick Langlois, Ph. D. in Economics and Finance, started his career at Louis Dreyfus bank and pursued most of his career at Rhône-Poulenc and Aventis SA as Executive Vice President and CFO. He currently is General Partner of PJL Conseil. He also serves as board member and non Executive Director of several biopharmaceutical companies in Europe and in the United-States, notably Shire plc, Newron Pharmaceuticals, Innate Pharma, Exonhit Therapeutics. His expertise in corporate development and mergers and acquisitions in the biotech and pharmaceutical areas will be a major input for the company’s development.
Nicolas Trebouta, MD, via his company Financière de la Montagne, has been since 2004 investing in biotechnology companies, directly or through funds. He has co-founded Chevrillon et Associé in 2000 and through this structure has achieved several LBO such as Picard (frozen food), CPI (printing company) or Alingia (insurance company). He is a medical doctor and shareholder of BioAlliance Pharma since 2008.
David H. Solomon, MD, serves as CEO of Zealand Pharma (Denmark). He has extensive experience in pharmacology research, having served as faculty member at Columbia University's College of Physicians and Surgeons in New York, NY as well as leadership positions at several biotechnology, pharmaceutical and medical device companies. From 2003-2006, Dr. Solomon led healthcare investing at Carrot Capital Healthcare Ventures.
About BioAlliance Pharma
Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products –– BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs. The company’s teams have the key competencies required to identify, develop and register drugs in Europe and the USA; the products’ commercialization rights are licensed to international commercial partners invested in the hospital setting. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life.
BioAlliance Pharma has developed an advanced product portfolio:
Specialty products
Loramyc®/Oravig® (oropharyngeal candidiasis in immunocompromised patients): Registered in 28 countries (EU US, Korea) Setofilm® (prevention and treatment of nausea and vomiting post chemo-radiotherapy and post operative) - Registered in EU
Sitavir® (Acyclovir Lauriad TM) (labialis herpes): Positive phase III final results; registration status
Fentanyl LauriadTM (chronic cancer pain): Positive preliminary Phase I results
Orphan Oncology products
Livatag® (Doxorubicin Transdrug™) in primary) liver cancer: Phase II results on survival
Clonidine LauriadTM (mucositis): Phase II on going
AMEP® (invasive melanoma): Phase I on going
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2009 Reference Document filed with the AMF on June 29, 2010, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).
CONTACT:
BioAlliance Pharma SA
Dominique Costantini, CEO
Tel.: +33 1 45 58 76 01
[email protected]
or
Judith Greciet, COO
Tel +33 1 45 58 70 61
[email protected]
or
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
[email protected]
or
ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59
[email protected]
KEYWORDS: Europe France
INDUSTRY KEYWORDS: Health Biotechnology Oncology Pharmaceutical
MEDIA:
| Logo |